Jardiance and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Jardiance (empagliflozin), especially for people who are female, 60+ old, also take Ibrance, and have Breast cancer female.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Jardiance. It is created by eHealthMe based on reports of 43,725 people who have side effects when taking Jardiance from the FDA, and is updated regularly.

What is Jardiance?

Jardiance has active ingredients of empagliflozin. It is often used in hyperglycemia. eHealthMe is studying from 44,459 Jardiance users. Check the latest studies of Jardiance.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,067 drugs and 914 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

On Jul, 31, 2026

43,725 people reported to have side effects when taking Jardiance.
Among them, 21 people (0.05%) have Neoplasm progression.

Could Jardiance cause Neoplasm progression?

Among these 21 people:

What is the gender of people who have Neoplasm progression when taking Jardiance? *

female: 61.9 %
male: 38.1 %

What is the age of people who have Neoplasm progression when taking Jardiance? *

What are other drugs people take besides Jardiance? *

What are other side effects people have besides Neoplasm progression? *

Nausea (feeling of having an urge to vomit): 3 people, 14.29%
High Blood Pressure: 3 people, 14.29%
Fatigue (feeling of tiredness): 3 people, 14.29%
Memory Loss: 3 people, 14.29%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 14.29%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 14.29%
Hypotension (abnormally low blood pressure): 2 people, 9.52%
Gait Disturbance: 2 people, 9.52%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 2 people, 9.52%
Pain: 2 people, 9.52%

What are the existing conditions these people have? *

Breast Cancer Female: 10 people, 47.62%
Diabetes: 5 people, 23.81%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 3 people, 14.29%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 3 people, 14.29%
Breast Cancer Metastatic: 2 people, 9.52%
Dyslipidaemia (abnormal amount of lipids): 2 people, 9.52%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 9.52%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 9.52%
Type 2 Diabetes: 1 person, 4.76%
Hypersensitivity: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Jardiance and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Jardiance:

Jardiance (44,459 reports)

Browse all side effects of Jardiance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,067 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (914 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on empagliflozin (the active ingredients of Jardiance) and Jardiance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.